<DOC>
	<DOCNO>NCT01224353</DOCNO>
	<brief_summary>The purpose study evaluate efficacy overall neuropathic sensory symptom improvement Thioctacid tablet 600mg daily vs. placebo 6-weeks ' treatment Chinese diabetic patient distal symmetric polyneuropathy ( DSP ) .</brief_summary>
	<brief_title>Efficacy Safety Study Thioctacid Oral Tablets 600mg Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Subjects must fulfil follow criterion appropriate enter Registry ( Visit 2 ) 1 . Provision inform consent 2 . Females male age 18 75 ( inclusive ) , definitely diagnose diabetes 3 . HbA1C &lt; 10％ 4 . Moderate neuropathy accord Neuropathy Disability Score ( NDS ) &gt; = 4 point . Difference score leave right foot high 2 point 5 . Total Symptom Score ( TSS ) &gt; 6.5 point 6 . At least one four symptom TSS occur continuously last 3 month screen 7 . Other concomitant treatment ( drug dosage ) stable 1 month screen Subjects must fulfil follow criterion randomization： 8 . TSS &gt; 5 point 9 . TSS range ( maximum TSS minimum TSS Runin Period ) &lt; 3 point Runin Period 10 . Compliance Runin Period &gt; 85 % 1 . Neurologic disease diabetic neuropathy may produce weakness , sensory loss , autonomic symptom test abnormality 2 . Peripheral vascular disease severe enough cause intermittent claudication ischemic ulcer 3 . Patients hospitalize due glucopenia ketoacidosis last 3 month 4 . Present ulcer low limb cause 5 . Antioxidant therapy within last 1 month screening ( Vitamin E &gt; 400IU , Vitamin C &gt; 200mg daily continuous 2 week ) 6 . Any ALA therapy within last1 month screen 7 . Opioid analgesic therapy within last 1 month screen 8 . History mental , psychological behavioral condition render patient unable follow protocol 9 . History malignant tumor past 5 year except basal cell carcinoma 10 . Any severe systematic disease , investigator 's discretion , make undesirable patient participate trial could jeopardize compliance trial protocol , 11 . ALT AST &gt; 2.5 ´ upper limit reference range 12 . Cr &gt; 1.8mg/dL ( &gt; 159µmol/L ) male &gt; 1.6mg/dL ( &gt; 141µmol/L ) females 13 . History hypersensitive active ingredient excipients ALA 14 . Participation clinical study treatment nonapproved experimental medication last 1 month 15 . Pregnant breastfeed woman , woman childbearing age without appropriate contraception measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>